Article
Eisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - report
Rating:
0.0
Views:
37
Likes:
1
Library:
1
An influential drug pricing research group said Eisai Co Ltd and Biogen Inc's new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value